Related references
Note: Only part of the references are listed.
Review
Clinical Neurology
Susana Otero-Romero et al.
Summary: New evidence supports the lack of causal link between MS and vaccination, with consensus statements emphasizing the importance of starting vaccination early. Timing adjustments for vaccine administration are necessary to ensure safety and optimize vaccine responses in light of potential interference from DMDs. Patients on B-cell depleting therapies like Ocrelizumab are at risk of reduced immunogenicity to vaccines, highlighting the implications for upcoming SARS-CoV-2 vaccination.
CURRENT OPINION IN NEUROLOGY
(2021)
Article
Clinical Neurology
Steve Simpson-Yap et al.
Summary: Using data from 12 sources in 28 countries, this study examined the characteristics of COVID-19 severity in people with MS, particularly those taking immunosuppressive therapies. The results showed that older age, progressive MS phenotype, and higher disability were associated with worse COVID-19 outcomes. Additionally, rituximab was consistently associated with increased risk of hospitalization, ICU admission, and need for ventilation, while ocrelizumab was mainly associated with hospitalization and ICU admission.
Article
Infectious Diseases
Tal Brosh-Nissimov et al.
Summary: A study in Israel showed that a minority of fully vaccinated individuals with significant comorbidities may still develop severe COVID-19, with a high mortality rate. Further research on this vulnerable population may help improve their protection.
CLINICAL MICROBIOLOGY AND INFECTION
(2021)
Article
Biochemistry & Molecular Biology
Sokratis A. Apostolidis et al.
Summary: Patients with multiple sclerosis on anti-CD20 monotherapy exhibit significantly reduced SARS-CoV-2-specific antibodies and memory B cells, while CD4(+) and CD8(+) T cells are robustly activated compared to healthy controls after receiving BNT162b2 or mRNA-1273 mRNA vaccination.
Article
Clinical Neurology
Kevin Bigaut et al.
Summary: This study compares the humoral response after SARS-CoV-2 infection in MS patients receiving different DMTs, finding lower IgG index in patients treated with fingolimod or anti-CD20 mAb. These patients may be at risk of recurrent infection and could benefit from anti-SARS-CoV-2 vaccination, with the need to evaluate humoral response after vaccination and the delay before vaccination.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION
(2021)
Article
Immunology
Maurice Steenhuis et al.
Summary: The study found that most convalescent individuals were seropositive at the initial sampling, with only one seroreverting during follow-up analysis. Antibody levels declined 2-5 months after symptom onset, with a slowing rate of decline during extended follow-up indicating long-term immunological memory.
CLINICAL & TRANSLATIONAL IMMUNOLOGY
(2021)
Article
Clinical Neurology
Amit Bar-Or et al.
Article
Immunology
Erik H. Vogelzang et al.
JOURNAL OF IMMUNOLOGY
(2020)
